Canada markets closed

TransMedics Group, Inc. (TMDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
127.99+3.55 (+2.85%)
At close: 04:00PM EDT
127.82 -0.17 (-0.13%)
After hours: 07:11PM EDT

TransMedics Group, Inc.

200 Minuteman Road
Suite 302
Andover, MA 01810
United States
978 552 0900
https://www.transmedics.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees584

Key Executives

NameTitlePayExercisedYear Born
Dr. Waleed H. Hassanein M.D.Founder, President, CEO & Director1.82M13.38M1968
Mr. Stephen GordonCFO, Treasurer & Secretary909.62k1.31M1968
Mr. Nicholas CorcoranSenior Vice President of Supply Chain & Operations812.07kN/A1983
Mr. Anil RanganathSenior VP, General Counsel & Corporate Secretary561.67kN/AN/A
Dr. Tamer I. Khayal M.D.Chief Commercial Officer900.11k5.45M1969
Mr. Mark AndersonSenior Director of Technology DevelopmentN/AN/AN/A
Ms. Susan GoodmanVice President of Human ResourcesN/AN/AN/A
Ms. Miriam C. Provost Ph.D.Vice President of Global Regulatory Affairs535.93k390.25k1961
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Corporate Governance

TransMedics Group, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 3. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.